The ROMA algorithm comprises determination of serum concentrations of two tumour markers—CA125 and HE4—and a statistical estimation of the risk of a malignant ovarian tumour, taking into account the patient’s menopausal status. This evidence concerns the gene WFDC2 and ovarian neoplasm.